These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19283891)

  • 1. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Hoshida Y; Golub TR
    N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283891
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effectiveness of long-acting interferon (peginterferon)].
    Kondo Y; Tateishi R; Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
    [No Abstract]   [Full Text] [Related]  

  • 3. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
    Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
    Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Koretz RL; Gluud C
    N Engl J Med; 2009 Mar; 360(11):1151; author reply 1152-3. PubMed ID: 19279350
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antiviral treatments during cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2006; 30(6-7):899-902. PubMed ID: 16885876
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis.
    Ji F; Zhang S; Deng H; Li Z
    J Hepatol; 2013 Jun; 58(6):1262-4. PubMed ID: 23395693
    [No Abstract]   [Full Text] [Related]  

  • 7. Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?
    Toyoda H; Kumada T; Tada T
    J Hepatol; 2013 Apr; 58(4):838-9. PubMed ID: 23207142
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?".
    Ogawa E; Furusyo N; Hayashi J;
    J Hepatol; 2013 Apr; 58(4):839-40. PubMed ID: 23211318
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HCV-HBV infection].
    Imamura M; Chayama K
    Nihon Rinsho; 2006 Jul; 64(7):1310-3. PubMed ID: 16838649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summaries for patients. Long-term effects of antiviral treatment for hepatitis C.
    Ann Intern Med; 2005 Jan; 142(2):I51. PubMed ID: 15657153
    [No Abstract]   [Full Text] [Related]  

  • 12. [Long-term prognosis of chronic hepatitis C--special reference to interferon therapy].
    Arakawa Y
    Nihon Naika Gakkai Zasshi; 1998 Mar; 87(3):480-5. PubMed ID: 9577579
    [No Abstract]   [Full Text] [Related]  

  • 13. [The prophylaxis of hepatocellular carcinoma by interferon-alpha in virus-induced cirrhosis].
    Merle P; Zoulim F; Vitvitski L; Trépo C
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1166-76. PubMed ID: 11173729
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Poynard T; Ratziu V
    N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283890
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term effects of interferon-based therapy for chronic hepatitis C.
    Yu ML; Huang CF; Dai CY; Huang JF; Chuang WL
    Oncology; 2007; 72 Suppl 1():16-23. PubMed ID: 18087178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma and interferon therapy in HCV compensated cirrhosis: evaluation in relation to virological response.
    Testino G; Icardi G
    Hepatogastroenterology; 2005; 52(63):4 p preceding table of contents. PubMed ID: 15966175
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
    Fukuda A
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):493-6. PubMed ID: 15359848
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antiviral treatment reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related chronic hepatitis and cirrhosis].
    Kasahara A; Hiramatsu N
    Nihon Rinsho; 2011 May; 69 Suppl 4():314-8. PubMed ID: 22096937
    [No Abstract]   [Full Text] [Related]  

  • 20. [Peginterferon alpha and ribavirin therapy for difficult-to-treat chronic hepatitis C patients].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2002; 56 Suppl 4():51-4. PubMed ID: 14750261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.